StemCell Therapeutics is a Canadian microcap with interesting immuno-oncology programs, in particular the anti-CD47 program. This is a hot field. The company acquired much of its pipe through an acquisition of Trillium Therapeutics in April of 2013. Everything is preclinical or Phase 1 at this point, and since it is a penny stock, it is subject to a) nasty financing deals, and b) slow movement in certain programs.
The board logo is CD47 in complex with SIRP, the pathway targeted by the lead program.
The website doesn't provide much in the way of links to publications or IP, so we'll have to do that digging on our own. Company has officially changed it name to Trillium Therapeutics and is now listed on the NASDAQ.
Website: Trillium Therapeutics |
